A pilot study to investigate the potential of mass spectrometry profiling in the discovery of novel serum markers in chronic renal disease

Proteomics - Clinical Applications

Volumn 5, Issue 9-10, 2011, Pages 523-531

  Thompson, Douglas ^a   Develter, Willem ^b   Cairns, David A ^b,c   Barrett, Jennifer H ^c   Perkins, David A ^b   Stanley, Anthea J ^b   Mooney, Andrew ^b   Selby, Peter J ^b   Banks, Rosamonde E ^b  

^a LEEDS GENERAL INFIRMARY   (United Kingdom)

^b ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^c UNIVERSITY OF LEEDS   (United Kingdom)

Author keywords

Graft dysfunction; Renal transplant; SELDI; Serum

Indexed keywords

BETA 2 MICROGLOBULIN; BIOLOGICAL MARKER;

ADULT; AGED; ARTICLE; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; HEMODIALYSIS; HUMAN; IMMUNOASSAY; INTERMETHOD COMPARISON; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; MALE; NEPHELOMETRY; PILOT STUDY; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEOMICS; QUALITY CONTROL; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; VALIDATION PROCESS;

ADULT; AGED; AGED, 80 AND OVER; BIOLOGICAL MARKERS; FEMALE; HUMANS; KIDNEY TRANSPLANTATION; MACROGLOBULINS; MALE; MIDDLE AGED; NEPHELOMETRY AND TURBIDIMETRY; PILOT PROJECTS; PRINCIPAL COMPONENT ANALYSIS; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 80053655331     PISSN: 18628346     EISSN: 18628354     Source Type: Journal    
DOI: 10.1002/prca.201100009     Document Type: Article

References (40)

1. Yates, P. J., Nicholson, M. L., The aetiology and pathogenesis of chronic allograft nephropathy. Transpl. Immunol. 2006, 16, 148-157.
2. Nankivell, B. J., Chapman, J. R., Chronic allograft nephropathy: current concepts and future directions. Transplantation 2006, 81, 643-654.
3. American Society of Nephrology Renal Research Report. J. Am. Soc. Nephrol. 2005, 16, 1886-1903.
4. Pascual, M., Theruvath, T., Kawai, T., Tolkoff-Rubin, N. et al., Strategies to improve long-term outcomes after renal transplantation. N. Engl. J. Med. 2002, 346, 580-590.
5. Parrish, A. E., Complications of percutaneous renal biopsy: a review of 37 years' experience. Clin Nephrol 1992, 38, 135-141.
6. Perrone, R. D., Madias, N. E., Levey, A. S., Serum creatinine as an index of renal function: new insights into old concepts. Clin. Chem. 1992, 38, 1933-1953.
7. Levey, A. S., Measurement of renal function in chronic renal disease. Kidney Int. 1990, 38, 167-184.
8. van Timmeren, M. M., Vaidya, V. S., van Ree, R. M., Oterdoom, L. H. et al., High urinary excretion of kidney injury molecule-1 is an independent predictor of graft loss in renal transplant recipients. Transplantation 2007, 84, 1625-1630.
9. Muthukumar, T., Dadhania, D., Ding, R., Snopkowski, C. et al., Messenger RNA for FOXP3 in the urine of renal-allograft recipients. N. Engl. J. Med. 2005, 353, 2342-2351.
10. Gwinner, W., Renal transplant rejection markers. World J. Urol. 2008, 25, 445-455.
11. Smith, M. P., Banks, R. E., Wood, S. L., Lewington, A. J. et al., Application of proteomic analysis to the study of renal diseases. Nat. Rev. Nephrol. 2009, 5, 701-712.
12. Findeisen, P., Neumaier, M., Mass spectrometry based proteomics profiling as diagnostic tool in oncology: current status and future perspective. Clin Chem. Lab. Med. 2009, 47, 666-684.
13. Hortin, G. L., Can mass spectrometric protein profiling meet desired standards of clinical laboratory practice? Clin. Chem. 2005, 51, 3-5.
14. Koomen, J. M., Li, D., Xiao, L. C., Liu, T. C. et al., Direct tandem mass spectrometry reveals limitations in protein profiling experiments for plasma biomarker discovery. J. Proteome Res. 2005, 4, 972-981.
15. Cairns, D. A., Thompson, D., Perkins, D. N., Stanley, A. J. et al., Proteomic profiling using mass spectrometry - does normalising by total ion current potentially mask some biological differences? Proteomics 2008, 8, 21-27.
16. Banks, R. E., Stanley, A. J., Cairns, D. A., Barrett, J. H. et al., Influences of blood sample processing on low-molecular-weight proteome identified by surface-enhanced laser desorption/ionization mass spectrometry. Clin. Chem. 2005, 51, 1637-1649.
17. Cairns, D. A., Perkins, D. N., Stanley, A. J., Thompson, D. et al., Integrated multi-level quality control for proteomic profiling studies using mass spectrometry. BMC Bioinformatics 2008, 9, 519.
18. Wagner, M., Naik, D., Pothen, A., Protocols for disease classification from mass spectrometry data. Proteomics 2003, 3, 1692-1698.
19. Rogers, M. A., Clarke, P., Noble, J., Munro, N. P. et al., Proteomic profiling of urinary proteins in renal cancer by Surface Enhanced Laser Desorption Ionisation (SELDI) and neural network analysis: identification of key issues affecting potential clinical utility. Cancer Res. 2003, 63, 6971-6983.
20. Niwa, T., Mass spectrometry in the search for uremic toxins. Mass Spectrom. Rev. 1997, 16, 307-332.
21. Apweiler, R., Bairoch, A., Wu, C. H., Barker, W. C. et al., UniProt: the Universal Protein knowledgebase. Nucleic Acids Res. 2004, 32, D115-D119.
22. Dihazi, H., Muller, G. A., Lindner, S., Meyer, M. et al., Characterization of diabetic nephropathy by urinary proteomic analysis: identification of a processed ubiquitin form as a differentially excreted protein in diabetic nephropathy patients. Clin. Chem. 2007, 53, 1636-1645.
23. Devarajan, P., Krawczeski, C. D., Nguyen, M. T., Kathman, T. et al., Proteomic identification of early biomarkers of acute kidney injury after cardiac surgery in children. Am. J. Kidney Dis. 2010, 56, 632-642.
24. Suzuki, M., Ross, G. F., Wiers, K., Nelson, S. et al., Identification of a urinary proteomic signature for lupus nephritis in children. Pediatr. nephrol. 2007, 22, 2047-2057.
25. Chen, L., Ho, D. W. Y., Lee, N. P., Sun, S. et al., Enhanced detection of early hepatocellular carcinoma by SELDI-TOF proteomic signature combined with alpha-fetoprotein marker. Ann. Surg. Oncol. 2011, 17, 2518-2525.
26. Drueke, T. B., Massy, Z. A., Beta2-Microglobulin. Semin. Dial. 2009, 22, 378-380.
27. McCarthy, J. T., Williams, A. W., Johnson, W. J., Serum beta 2-microglobulin concentration in dialysis patients: importance of intrinsic renal function. J. Lab. Clin. Med. 1994, 123, 495-505.
28. Okuno, S., Ishimura, E., Kohno, K., Fujino-Katok, Y. et al., Serum beta2-microglobulin level is a significant predictor of mortality in maintenance haemodialysis patients. Nephrol. Dial. Transplant. 2009, 24, 571-577.
29. Nankivell, B. J., Borrows, R. J., Fung, C. L., O'Connell, P. J. et al., The natural history of chronic allograft nephropathy. N. Engl. J. Med. 2003, 349, 2326-2333.
30. O'Riordan, E., Orlova, T. N., Podust, V. N., Chander, P. N. et al., Characterization of urinary peptide biomarkers of acute rejection in renal allografts. Am. J. Transplant. 2007, 7, 1-11.
31. Schaub, S., Rush, D., Wilkins, J., Gibson, I. W. et al., Proteomic-based detection of urine proteins associated with acute renal allograft rejection. J. Am. Soc. Nephrol. 2004, 15, 219-227.
32. Schaub, S., Wilkins, J. A., Antonovici, M., Krokhin, O. et al., Proteomic-based identification of cleaved urinary beta2-microglobulin as a potential marker for acute tubular injury in renal allografts. Am. J. Transplant. 2005, 5, 729-738.
33. Oetting, W. S., Rogers, T. B., Krick, T. P., Matas, A. J. et al., Urinary beta2-microglobulin is associated with acute renal allograft rejection. Am. J. Kidney Dis. 2006, 47, 898-904.
34. Wittke, S., Haubitz, M., Walden, M., Rohde, F. et al., Detection of acute tubulointerstitial rejection by proteomic analysis of urinary samples in renal transplant recipients. Am. J. Transplant. 2005, 5, 2479-2488.
35. Reichelt, O., Muller, J., von, E. F., Driesch, D. et al., Prediction of renal allograft rejection by urinary protein analysis using ProteinChip Arrays (surface-enhanced laser desorption/ionization time-of-flight mass spectrometry). Urology 2006, 67, 472-475.
36. Clarke, W., Silverman, B. C., Zhang, Z., Chan, D. W. et al., Characterization of renal allograft rejection by urinary proteomic analysis. Ann. Surg. 2003, 237, 660-665.
37. O'Riordan, E., Orlova, T. N., Mendelev, N., Patschan, D. et al., Urinary proteomic analysis of chronic allograft nephropathy. Proteomics Clin. Appl. 2008, 2, 1025-1035.
38. Zhou, S. T., Yan, S. H., Yang, C., Zeng, N. et al., Construction of protein fingerprint signature in serum and its significance for early diagnosis with chronic allograft nephropathy. Zhonghua Zhong Liu Za Zhi 2006, 86, 1966-1969.
39. Aggelis, V., Craven, R. A., Peng, J., Harnden, P. et al., Proteomic identification of differentially expressed plasma membrane proteins in renal cell carcinoma by stable isotope labelling of a von Hippel-Lindau transfectant cell line model. Proteomics 2009, 9, 2118-21130.
40. Vasudev, N. S., Sim, S., Cairns, D. A., Craven, R. A. et al., Pre-operative urinary cathepsin D is associated with survival in patients with renal cell carcinoma. Br. J. Cancer 2009, 101, 1175-1182.